BBOT stock

BridgeBio Oncology Therapeutics, Inc. (BBOT) financials · $610.4M cap

Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT

BridgeBio Oncology Therapeutics, Inc. (BBOT) $610.4M cap.

Cached income statement (latest stored periods)
LineQ2 2026Q1 2026
Revenue$3.55M$3.94M
Operating Income-$60.2M-$46.2M
Net Income-$56.5M-$42.1M
EPS (Diluted)-$705.00-$526.00
Cached balance sheet (latest stored periods)
LineQ2 2026Q1 2026
Total Assets$376.7M$417.6M
Current Assets$242.4M$266.5M
Cash & Equivalents$54.1M$52.7M
PP&E$878.0K$938.0K
Total Liabilities$53.6M$45.4M
Current Liabilities$51.6M$43.3M
Shareholders' Equity$323.1M$372.3M
Retained Earnings-$455.1M-$398.7M
Cached annual cash flow
LineFY2024
Operating Cash Flow-$763.8K
Investing Cash Flow-$184.0M
Financing Cash Flow$186.5M
These statements as JSON? API free 100/day

FAQ

What is BBOT P/E and revenue?

BridgeBio Oncology Therapeutics, Inc. (BBOT) $610.4M cap.

What is BBOT revenue?

BridgeBio Oncology Therapeutics, Inc. last cached revenue is $3.55M (Q2 2026).

Is BBOT profitable?

BridgeBio Oncology Therapeutics, Inc. last cached net income is -$56.5M (Q2 2026).

What are BBOT total assets?

BridgeBio Oncology Therapeutics, Inc. last cached total assets are $376.7M (Q2 2026).

What is BBOT free cash flow?

No cached cash-flow row for BBOT yet.

Not investment advice. Cached statements, not a live tape.